{"brief_title": "Reversal of Ventricular Remodeling With Toprol-XL", "brief_summary": "The purpose of this study is to determine whether treatment with Toprol-XL for 12 months in asymptomatic heart failure subjects will improve their heart structure and thus prevent the progression to symptomatic disease.", "condition": ["Heart Failure, Congestive"], "intervention_type": ["Drug", "Drug", "Drug"], "intervention_name": ["Seloken ZOK/Toprol-XL", "Seloken ZOK/Toprol-XL", "Placebo"], "description": ["50 mg", "200 mg"], "other_name": ["Toprol-XL", "Toprol-XL"], "criteria": "Inclusion Criteria: - Diagnosis of stable asymptomatic heart failure. - Documented ejection fraction less than 0.40. - Must be able to comply with all study procedures. Exclusion Criteria: - Taken B-blocker therapy for longer than 1 week within 6 months prior to randomization. - Have heart problems that would not allow B-blocker therapy. - Receiving B-blockers therapy for any medical reason including topical B-blockers that might cause systemic absorption (e.g., glaucoma). - Undergone certain heart surgeries, such as, prior heart transplant or cardiomyoplasty. - Have certain heart diseases. - Pregnant or breast feeding. - Unlikely to survive.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Heart Failure", "Ventricular Remodeling", "Metoprolol"], "id": "NCT00038077"}